11.13.20
6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Help me get ahead. $200/year

Newsletters

    308 articles
  • First
  • Previous
    • 1 of 31
  • Next
  • Last
Quest bought Pack Health for $123M cash. Trials
4.21.23
6 min. Read
New digital health CPT code hopefuls. Trials
4.14.23
5 min. Read
Breaking: Pear Therapeutics files for Chapter 11 bankruptcy
4.07.23
4 min. Read
Pricing Database update: 60+ digital health prices.
4.05.23
3 min. Read
E&O readers analyze fate of Pear, PDTs. FDA-AI
3.31.23
8 min. Read
Seven secret health tech funding deals
3.27.23
3 min. Read
FDA waiver ends Nov 7. Withings ScanWatch recall, revs
3.24.23
10 min. Read
Pear seeks buyer. Lobbying for a CMS benefit category.
3.17.23
6 min. Read
CMS to pay for VR-based CBT. No HCPCS for CanvasDx.
3.10.23
8 min. Read
Omada Health’s all-time participant numbers. IBM employee benefits.
3.08.23
6 min. Read
  • First
  • Previous
    • 1 of 31
  • Next
  • Last